WO2023185760A1 - 一种产丁酸的益生菌及其构建方法和应用 - Google Patents
一种产丁酸的益生菌及其构建方法和应用 Download PDFInfo
- Publication number
- WO2023185760A1 WO2023185760A1 PCT/CN2023/084163 CN2023084163W WO2023185760A1 WO 2023185760 A1 WO2023185760 A1 WO 2023185760A1 CN 2023084163 W CN2023084163 W CN 2023084163W WO 2023185760 A1 WO2023185760 A1 WO 2023185760A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- gene
- probiotic
- coa
- probiotics
- genes
- Prior art date
Links
- 239000006041 probiotic Substances 0.000 title claims abstract description 93
- 235000018291 probiotics Nutrition 0.000 title claims abstract description 93
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 title claims abstract description 90
- 230000000529 probiotic effect Effects 0.000 title claims abstract description 44
- 238000000034 method Methods 0.000 title claims abstract description 16
- 239000003814 drug Substances 0.000 claims abstract description 24
- 208000008589 Obesity Diseases 0.000 claims abstract description 21
- 208000010706 fatty liver disease Diseases 0.000 claims abstract description 21
- 235000020824 obesity Nutrition 0.000 claims abstract description 21
- 241001465754 Metazoa Species 0.000 claims abstract description 19
- 208000024891 symptom Diseases 0.000 claims abstract description 18
- 239000002537 cosmetic Substances 0.000 claims abstract description 15
- 235000013305 food Nutrition 0.000 claims abstract description 14
- 239000000126 substance Substances 0.000 claims abstract description 7
- 108090000623 proteins and genes Proteins 0.000 claims description 89
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 38
- 230000015572 biosynthetic process Effects 0.000 claims description 37
- 238000003786 synthesis reaction Methods 0.000 claims description 36
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 claims description 34
- 201000010099 disease Diseases 0.000 claims description 31
- 239000013612 plasmid Substances 0.000 claims description 29
- 206010061218 Inflammation Diseases 0.000 claims description 20
- 208000004930 Fatty Liver Diseases 0.000 claims description 19
- 206010019708 Hepatic steatosis Diseases 0.000 claims description 19
- 230000004054 inflammatory process Effects 0.000 claims description 19
- 231100000240 steatosis hepatitis Toxicity 0.000 claims description 19
- 241000588724 Escherichia coli Species 0.000 claims description 17
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 17
- 229940079593 drug Drugs 0.000 claims description 16
- 230000037361 pathway Effects 0.000 claims description 16
- 241000894006 Bacteria Species 0.000 claims description 13
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 claims description 12
- 108010006229 Acetyl-CoA C-acetyltransferase Proteins 0.000 claims description 12
- 101100398785 Streptococcus agalactiae serotype V (strain ATCC BAA-611 / 2603 V/R) ldhD gene Proteins 0.000 claims description 12
- 101100386830 Zymomonas mobilis subsp. mobilis (strain ATCC 31821 / ZM4 / CP4) ddh gene Proteins 0.000 claims description 12
- 101150014383 adhE gene Proteins 0.000 claims description 12
- 206010009887 colitis Diseases 0.000 claims description 12
- 210000001072 colon Anatomy 0.000 claims description 12
- 238000010276 construction Methods 0.000 claims description 12
- 230000014509 gene expression Effects 0.000 claims description 12
- 101150026107 ldh1 gene Proteins 0.000 claims description 12
- 101150041530 ldha gene Proteins 0.000 claims description 12
- 102100037388 Gasdermin-D Human genes 0.000 claims description 8
- 101001026262 Homo sapiens Gasdermin-D Proteins 0.000 claims description 8
- 239000003674 animal food additive Substances 0.000 claims description 8
- 238000003780 insertion Methods 0.000 claims description 8
- 230000037431 insertion Effects 0.000 claims description 8
- 208000030159 metabolic disease Diseases 0.000 claims description 8
- 230000000770 proinflammatory effect Effects 0.000 claims description 7
- 101710120269 Acyl-CoA thioester hydrolase YbgC Proteins 0.000 claims description 6
- 108010021809 Alcohol dehydrogenase Proteins 0.000 claims description 6
- 108010087894 Fatty acid desaturases Proteins 0.000 claims description 6
- -1 IL-1β Proteins 0.000 claims description 6
- 108010088350 Lactate Dehydrogenase 5 Proteins 0.000 claims description 6
- 108090000992 Transferases Proteins 0.000 claims description 6
- 210000000349 chromosome Anatomy 0.000 claims description 6
- 108030005660 3-hydroxybutyryl-CoA dehydratases Proteins 0.000 claims description 5
- 108010055682 3-hydroxybutyryl-CoA dehydrogenase Proteins 0.000 claims description 5
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 5
- 239000005516 coenzyme A Substances 0.000 claims description 5
- 229940093530 coenzyme a Drugs 0.000 claims description 5
- 230000006378 damage Effects 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 241000186000 Bifidobacterium Species 0.000 claims description 4
- 241000193171 Clostridium butyricum Species 0.000 claims description 4
- RGJOEKWQDUBAIZ-IBOSZNHHSA-N CoASH Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O[C@H]1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-IBOSZNHHSA-N 0.000 claims description 4
- 102000004127 Cytokines Human genes 0.000 claims description 4
- 108090000695 Cytokines Proteins 0.000 claims description 4
- 241000194033 Enterococcus Species 0.000 claims description 4
- 241000186660 Lactobacillus Species 0.000 claims description 4
- 241000194017 Streptococcus Species 0.000 claims description 4
- 108010012901 Succinate Dehydrogenase Proteins 0.000 claims description 4
- RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 claims description 4
- KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 claims description 4
- 230000007267 depressive like behavior Effects 0.000 claims description 4
- 230000006872 improvement Effects 0.000 claims description 4
- 229940039696 lactobacillus Drugs 0.000 claims description 4
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims description 3
- 241000186361 Actinobacteria <class> Species 0.000 claims description 3
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 3
- 108090001005 Interleukin-6 Proteins 0.000 claims description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 3
- 230000002860 competitive effect Effects 0.000 claims description 3
- 230000002757 inflammatory effect Effects 0.000 claims description 3
- 230000001575 pathological effect Effects 0.000 claims description 3
- 238000004904 shortening Methods 0.000 claims description 3
- 230000006399 behavior Effects 0.000 claims description 2
- 239000012528 membrane Substances 0.000 claims description 2
- 101710088194 Dehydrogenase Proteins 0.000 claims 2
- QHHKKMYHDBRONY-XQUJUNONSA-N 3-hydroxybutyryl-coenzyme a Chemical compound O[C@@H]1[C@@H](OP(O)(O)=O)[C@H](CO[P@](O)(=O)O[P@@](O)(=O)OCC(C)(C)[C@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@H](O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 QHHKKMYHDBRONY-XQUJUNONSA-N 0.000 claims 1
- 102100039894 Hemoglobin subunit delta Human genes 0.000 claims 1
- 108090001042 Hydro-Lyases Proteins 0.000 claims 1
- CRFNGMNYKDXRTN-CITAKDKDSA-N butyryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CCC)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CRFNGMNYKDXRTN-CITAKDKDSA-N 0.000 claims 1
- 230000003013 cytotoxicity Effects 0.000 claims 1
- 231100000135 cytotoxicity Toxicity 0.000 claims 1
- 230000000971 hippocampal effect Effects 0.000 claims 1
- 108700026220 vif Genes Proteins 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 abstract description 4
- 201000006704 Ulcerative Colitis Diseases 0.000 abstract description 4
- 241000699670 Mus sp. Species 0.000 description 32
- 101100297400 Rhizobium meliloti (strain 1021) phaAB gene Proteins 0.000 description 21
- 101100099093 Drosophila melanogaster term gene Proteins 0.000 description 12
- 101100278182 Mus musculus Dnd1 gene Proteins 0.000 description 12
- 101100463818 Pseudomonas oleovorans phaC1 gene Proteins 0.000 description 12
- 101150046540 phaA gene Proteins 0.000 description 12
- 239000008194 pharmaceutical composition Substances 0.000 description 12
- 101150026728 tesB gene Proteins 0.000 description 12
- 101150006429 atoB gene Proteins 0.000 description 10
- 101150103853 yciA gene Proteins 0.000 description 10
- 101100228546 Bacillus subtilis (strain 168) folE2 gene Proteins 0.000 description 9
- 101100494773 Caenorhabditis elegans ctl-2 gene Proteins 0.000 description 9
- 101100112369 Fasciola hepatica Cat-1 gene Proteins 0.000 description 9
- 108091026922 FnrS RNA Proteins 0.000 description 9
- 101100005271 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) cat-1 gene Proteins 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 101100280476 Streptococcus pneumoniae (strain ATCC BAA-255 / R6) fabM gene Proteins 0.000 description 9
- 230000001580 bacterial effect Effects 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 101150110984 phaB gene Proteins 0.000 description 9
- 101150097421 phaJ gene Proteins 0.000 description 9
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 230000006801 homologous recombination Effects 0.000 description 7
- 238000002744 homologous recombination Methods 0.000 description 7
- 208000035475 disorder Diseases 0.000 description 6
- 239000003651 drinking water Substances 0.000 description 6
- 235000020188 drinking water Nutrition 0.000 description 6
- 210000001320 hippocampus Anatomy 0.000 description 6
- 238000013116 obese mouse model Methods 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 238000011144 upstream manufacturing Methods 0.000 description 6
- 230000000994 depressogenic effect Effects 0.000 description 5
- 241000190857 Allochromatium vinosum Species 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 238000003304 gavage Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 241000607516 Aeromonas caviae Species 0.000 description 3
- 108091033409 CRISPR Proteins 0.000 description 3
- 238000010354 CRISPR gene editing Methods 0.000 description 3
- 241000193401 Clostridium acetobutylicum Species 0.000 description 3
- 241000193452 Clostridium tyrobutyricum Species 0.000 description 3
- 241001528539 Cupriavidus necator Species 0.000 description 3
- 208000004232 Enteritis Diseases 0.000 description 3
- 208000032843 Hemorrhage Diseases 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 241000589892 Treponema denticola Species 0.000 description 3
- 238000009227 behaviour therapy Methods 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 238000013227 male C57BL/6J mice Methods 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 241001302654 Escherichia coli Nissle 1917 Species 0.000 description 2
- 208000009329 Graft vs Host Disease Diseases 0.000 description 2
- 201000001431 Hyperuricemia Diseases 0.000 description 2
- 201000001916 Hypochondriasis Diseases 0.000 description 2
- 208000004356 Hysteria Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 108020004459 Small interfering RNA Proteins 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 208000012839 conversion disease Diseases 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000009266 disease activity Effects 0.000 description 2
- 230000006806 disease prevention Effects 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 230000030279 gene silencing Effects 0.000 description 2
- 238000010362 genome editing Methods 0.000 description 2
- 208000024908 graft versus host disease Diseases 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 210000005228 liver tissue Anatomy 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000013600 plasmid vector Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000006010 pyroptosis Effects 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000009182 swimming Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- 235000013618 yogurt Nutrition 0.000 description 2
- PKAUICCNAWQPAU-UHFFFAOYSA-N 2-(4-chloro-2-methylphenoxy)acetic acid;n-methylmethanamine Chemical compound CNC.CC1=CC(Cl)=CC=C1OCC(O)=O PKAUICCNAWQPAU-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 102000021527 ATP binding proteins Human genes 0.000 description 1
- 108091011108 ATP binding proteins Proteins 0.000 description 1
- 102000005416 ATP-Binding Cassette Transporters Human genes 0.000 description 1
- 108010006533 ATP-Binding Cassette Transporters Proteins 0.000 description 1
- 241000186046 Actinomyces Species 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 101100455969 Bacillus subtilis (strain 168) mdxK gene Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101150054117 CAT1 gene Proteins 0.000 description 1
- 241000282832 Camelidae Species 0.000 description 1
- 241000282421 Canidae Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000700114 Chinchillidae Species 0.000 description 1
- 208000022540 Consciousness disease Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 101000636215 Crotalus durissus terrificus Crotamine Proteins 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 208000027534 Emotional disease Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000699694 Gerbillinae Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 101150019065 HBD gene Proteins 0.000 description 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
- 208000027761 Hepatic autoimmune disease Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 201000006347 Intellectual Disability Diseases 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 241000282339 Mustela Species 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000007443 Neurasthenia Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 101710190786 PI protein Proteins 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 201000011252 Phenylketonuria Diseases 0.000 description 1
- 206010034912 Phobia Diseases 0.000 description 1
- 206010036774 Proctitis Diseases 0.000 description 1
- 241000282330 Procyon lotor Species 0.000 description 1
- 101710150114 Protein rep Proteins 0.000 description 1
- 208000003286 Protein-Energy Malnutrition Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 101710152114 Replication protein Proteins 0.000 description 1
- 241000555745 Sciuridae Species 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 208000020764 Sensation disease Diseases 0.000 description 1
- 208000027520 Somatoform disease Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 206010043561 Thrombocytopenic purpura Diseases 0.000 description 1
- 208000010011 Vitamin A Deficiency Diseases 0.000 description 1
- 206010047623 Vitamin C deficiency Diseases 0.000 description 1
- 206010047626 Vitamin D Deficiency Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 101150063416 add gene Proteins 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 208000021735 chronic enteritis Diseases 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 238000013373 clone screening Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 230000007357 depressive behavior Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000007938 effervescent tablet Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 239000003337 fertilizer Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000002727 hyperosmolar Effects 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000007413 intestinal health Effects 0.000 description 1
- 230000004609 intestinal homeostasis Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 235000020997 lean meat Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 101150003248 malK gene Proteins 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000004678 mucosal integrity Effects 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 230000002956 necrotizing effect Effects 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 235000015816 nutrient absorption Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 208000027753 pain disease Diseases 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 208000020861 perceptual disease Diseases 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 208000022821 personality disease Diseases 0.000 description 1
- 208000019899 phobic disease Diseases 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 235000020826 protein-energy malnutrition Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 208000010233 scurvy Diseases 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000006190 sub-lingual tablet Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 229940098466 sublingual tablet Drugs 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000010119 systemic immune function Effects 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 101150050362 thl gene Proteins 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
-
- A—HUMAN NECESSITIES
- A21—BAKING; EDIBLE DOUGHS
- A21D—TREATMENT, e.g. PRESERVATION, OF FLOUR OR DOUGH, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS; PRESERVATION THEREOF
- A21D13/00—Finished or partly finished bakery products
-
- A—HUMAN NECESSITIES
- A21—BAKING; EDIBLE DOUGHS
- A21D—TREATMENT, e.g. PRESERVATION, OF FLOUR OR DOUGH, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS; PRESERVATION THEREOF
- A21D2/00—Treatment of flour or dough by adding materials thereto before or during baking
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/13—Fermented milk preparations; Treatment using microorganisms or enzymes using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
- A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
- A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0008—Oxidoreductases (1.) acting on the aldehyde or oxo group of donors (1.2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/001—Oxidoreductases (1.) acting on the CH-CH group of donors (1.3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1025—Acyltransferases (2.3)
- C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/13—Transferases (2.) transferring sulfur containing groups (2.8)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/88—Lyases (4.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
- C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
- C12Y101/01027—L-Lactate dehydrogenase (1.1.1.27)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
- C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
- C12Y101/01028—D-Lactate dehydrogenase (1.1.1.28)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
- C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
- C12Y101/01157—3-Hydroxybutyryl-CoA dehydrogenase (1.1.1.157)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y102/00—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2)
- C12Y102/01—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2) with NAD+ or NADP+ as acceptor (1.2.1)
- C12Y102/01021—Glycolaldehyde dehydrogenase (1.2.1.21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y103/00—Oxidoreductases acting on the CH-CH group of donors (1.3)
- C12Y103/01—Oxidoreductases acting on the CH-CH group of donors (1.3) with NAD+ or NADP+ as acceptor (1.3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y103/00—Oxidoreductases acting on the CH-CH group of donors (1.3)
- C12Y103/01—Oxidoreductases acting on the CH-CH group of donors (1.3) with NAD+ or NADP+ as acceptor (1.3.1)
- C12Y103/01006—Fumarate reductase (NADH) (1.3.1.6)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y203/00—Acyltransferases (2.3)
- C12Y203/01—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
- C12Y203/01009—Acetyl-CoA C-acetyltransferase (2.3.1.9)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y208/00—Transferases transferring sulfur-containing groups (2.8)
- C12Y208/03—CoA-transferases (2.8.3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/02—Thioester hydrolases (3.1.2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y402/00—Carbon-oxygen lyases (4.2)
- C12Y402/01—Hydro-lyases (4.2.1)
- C12Y402/01055—3-Hydroxybutyryl-CoA dehydratase (4.2.1.55)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
本发明提供了一种产丁酸的益生菌及其构建方法和应用。该益生菌可以改善溃疡性结肠炎、抑郁症、肥胖和脂肪肝症状。在化工、食品、医药、动物饲料或化妆品领域中具有潜在应用。
Description
本发明涉及基因工程技术领域,具体涉及一种产丁酸的益生菌及其构建方法和其在化工、食品、医药、动物饲料或化妆品领域中的应用。
益生菌是通过定殖在人体内,改变宿主某一部位菌群组成的一类对宿主有益的活性微生物。通过调节宿主黏膜与系统免疫功能或通过调节肠道内菌群平衡,促进营养吸收保持肠道健康的作用,从而产生有利于健康作用的单微生物或组成明确的混合微生物。
目前,益生菌被广泛应用于化工、食品、医药、动物饲料或化妆品领域。例如,专利CN113968758A公开了益生菌在制作肥料中的应用。专利CN113908251A公开了一种包含益生菌的酸奶。专利CN114053310A、CN114129707A、CN114107122A、CN113999805A分别公开了益生菌在降脂、抗过敏、缓解通风及治疗高尿酸血症中的应用。专利CN114027397A公开了一种包含益生菌的饲料添加剂。专利CN113827521A公开了益生菌在化妆品领域的应用。
进一步的,通过对益生菌的改造进而治疗疾病。例如专利CN113604493A公开了一种高效表达LDH的益生菌能够有效的抑制细胞死亡、改善脑梗死体积、增强改善粘膜完整度、促进组织形态改善,对消化性溃疡、炎症性肠病和心脑血管疾病疗效。
但是现有技术中并没有公开本申请改造的益生菌,也没有公开其在改善溃疡性结肠炎、抑郁症、肥胖和脂肪肝症状。
发明内容
本发明人通过对丁酸合成途径(见图1)的仔细研究,制备了一种可以产生丁酸的益生菌,具体为将丁酸合成相关基因导入益生菌,该益生菌可以应用于化工、食品、医药、动物饲料或化妆品领域。尤其在于治疗或预防结肠炎或抑郁,以及改善肥胖或脂肪肝中的应用。在治疗上,与现有通过口服和直肠途径进行丁酸盐给药相比,靶向定位准确、解决了丁酸释放令人不快味道的局限性。
本发明的第一方面,提供了一种产丁酸的益生菌,所述益生菌的基因组中包含插入基因,所述的插入基因包含丁酸合成相关基因。
优选的,所述的丁酸合成相关基因包括3-羟基丁酰辅酶A脱氢酶基因(优选为hbd和/或phaB)、3-羟基丁酰辅酶A脱水酶基因(优选为crt和/或phaJ)和/或烯酰辅酶A还原酶基因(优选为ter)。
进一步优选的,所述的丁酸合成相关基因还包括乙酰乙酰辅酶A硫解酶基因(优选为atoB)或乙酰辅酶A乙酰基转移酶基因(优选为phaA和/或thl)。
更进一步优选的,所述的丁酸合成相关基因还包括酰基辅酶A硫酯酶基因(优选为tesB和/
或yciA),和/或辅酶A转移酶基因(优选为cat1)。
在本发明的一个具体实施方式中,所述的丁酸合成相关基因包括:
A)乙酰乙酰辅酶A硫解酶基因(优选为atoB)或乙酰辅酶A乙酰基转移酶基因(优选为phaA和/或thl);
B)3-羟基丁酰辅酶A脱氢酶基因(优选为hbd和/或phaB);
C)3-羟基丁酰辅酶A脱水酶基因(优选为crt和/或phaJ);
D)烯酰辅酶A还原酶基因(优选为ter);和,
E)酰基辅酶A硫酯酶基因(优选为tesB和/或yciA),和/或辅酶A转移酶基因(优选为cat1)。
优选的,atoB、tesB和yciA来源于大肠杆菌。
优选的,phaA来源于Cupriavidusnecator。
优选的,thl和cat1来源于Clostridium tyrobutyricum。
优选的,hbd和crt来源于Clostridium acetobutylicum。
优选的,ter来源于Treponema denticola。
优选的,phaB来源于Chromatium vinosum。
优选的,phaJ来源于Aeromonas caviae。
优选的,所述的插入基因中各基因为单拷贝或多拷贝。
优选的,所述的插入基因在质粒中表达或在染色体上表达。
在本发明的一个具体实施方式中,所述的插入基因插入益生菌染色体基因组的malEK、adhE或ldhA位点。
所述的插入基因可以均在一个质粒上,或者几个插入基因在一个质粒,其它在另一个质粒上。当然,插入基因也可以均插入同一个位点,或者不同的插入基因插入不同的位点,也可以相同的插入基因插入不同的位点(两个以上拷贝数)。
优选的,所述的益生菌不表达或降低表达丁酸合成竞争途径相关基因。所述的丁酸合成竞争途径相关基因包括但不限于乳酸脱氢酶A基因(优选为ldhA)、乙醛乙醇脱氢酶基因(优选为adhE)或和/富马酸还原酶基因(优选为frdA)中的一种或两种以上的组合。
在本发明的一个具体实施方式中,所述的丁酸合成竞争途径相关基因为乳酸脱氢酶A基因(优选为ldhA)和/或乙醛乙醇脱氢酶基因(优选为adhE)。
优选的,所述的不表达或降低表达包括但不限于敲除、敲低或沉默。
优选的,可以采用敲除(例如同源重组、CRISPR等等)或者敲低(例如加入siRNA等等)丁酸合成竞争途径相关基因的方式,使得益生菌中不表达或降低表达丁酸合成竞争途径相关基因。
优选的,所述的益生菌为肠道益生菌。
优选的,所述的益生菌包括但不限于酵母菌、益生芽孢菌、丁酸梭菌、乳杆菌、双歧杆菌、肠球菌、链球菌、放线菌或大肠杆菌。
在本发明的一个具体实施方式中,所述的益生菌为大肠杆菌。
本发明的第二方面,提供了一种上述的益生菌的构建方法,所述的构建方法包括将插入基因导入益生菌中。
优选的,所述的插入基因包含丁酸合成相关基因。
优选的,所述的丁酸合成相关基因包括3-羟基丁酰辅酶A脱氢酶基因(优选为hbd和/或phaB)、3-羟基丁酰辅酶A脱水酶基因(优选为crt和/或phaJ)和/或烯酰辅酶A还原酶基因(优选为ter)。
进一步优选的,所述的丁酸合成相关基因还包括乙酰乙酰辅酶A硫解酶基因(优选为atoB)或乙酰辅酶A乙酰基转移酶基因(优选为phaA和/或thl)。
更进一步优选的,所述的丁酸合成相关基因还包括酰基辅酶A硫酯酶基因(优选为tesB和/或yciA)或辅酶A转移酶基因(优选为cat1)。
在本发明的一个具体实施方式中,所述的丁酸合成相关基因包括:
A)乙酰乙酰辅酶A硫解酶基因(优选为atoB)或乙酰辅酶A乙酰基转移酶基因(优选为phaA和/或thl);
B)3-羟基丁酰辅酶A脱氢酶基因(优选为hbd和/或phaB);
C)3-羟基丁酰辅酶A脱水酶基因(优选为crt和/或phaJ);
D)烯酰辅酶A还原酶基因(优选为ter);和,
E)酰基辅酶A硫酯酶基因(优选为tesB和/或yciA),和/或辅酶A转移酶基因(优选为cat1)。
优选的,atoB、tesB和yciA来源于大肠杆菌。
优选的,phaA来源于Cupriavidusnecator。
优选的,thl和cat1来源于Clostridium tyrobutyricum。
优选的,hbd和crt来源于Clostridium acetobutylicum。
优选的,ter来源于Treponema denticola。
优选的,phaB来源于Chromatium vinosum。
优选的,phaJ来源于Aeromonas caviae。
优选的,所述的插入基因中各基因为单拷贝或多拷贝。
优选的,所述的插入基因在质粒中表达或在染色体上表达。
优选的,所述的导入为通过质粒将插入基因转化至益生菌中。
在本发明的一个具体实施方式中,所述的导入为将插入基因插入益生菌染色体基因组的malEK、adhE或ldhA位点。
所述的插入基因可以均在一个质粒上,或者几个插入基因在一个质粒,其他在另一个质粒上。当然,插入基因也可以均插入同一个位点,或者不同的插入基因插入不同的位点,也可以相同的插入基因插入不同的位点(两个以上拷贝数)。
优选的,所述的构建方法还包括敲除(例如同源重组、CRISPR等等)或敲低(例如加入siRNA等等)或沉默丁酸合成竞争途径相关基因,使得益生菌不表达或降低表达丁酸合成竞争途径相关基因。所述的丁酸合成竞争途径相关基因包括但不限于乳酸脱氢酶A基因(优选为ldhA)、乙醛乙醇脱氢酶基因(优选为adhE)或和/富马酸还原酶基因(优选为frdA)中的一种或两种以上的组合。
在本发明的一个具体实施方式中,所述的丁酸合成竞争途径相关基因为乳酸脱氢酶A基因(优选为ldhA)和/或乙醛乙醇脱氢酶基因(优选为adhE)。
优选的,所述的益生菌为肠道益生菌。
优选的,所述的益生菌选自酵母菌、益生芽孢菌、丁酸梭菌、乳杆菌、双歧杆菌、肠球菌、链球菌、放线菌或大肠杆菌。
在本发明的一个具体实施方式中,所述的益生菌为大肠杆菌。
在本发明的一个具体实施方式中,采用pRE112自杀质粒(Addgene:43828)同源重组体系对底盘细胞进行基因组编辑,敲除竞争途径相关基因,同时插入单拷贝或多拷贝丁酸合成相关基因atoB、phaA
或thl,hbd或phaB,crt或phaJ,ter以及tesB、yciA或cat1,得到所述产丁酸的大肠杆菌。
所述pRE112自杀质粒同源重组体系,即将待敲除基因上下游片段,或待插入基因及其待插入上下游片段克隆到pRE112质粒载体上,通过接合等使其进入宿主菌EcN,由于在EcN中不存在复制基因启始所需的复制蛋白(Pi蛋白),其无法复制,在外界选择性压力的作用下,自杀性质粒载体所携带的突变基因与EcN染色体上的野生型基因发生二次同源重组,得到目的突变株。
在本发明的一个具体实施方式中,在malEK位点顺次插入atoB(或phaA或thl)和hbd(或phaB)表达框、crt(或phaJ)和ter表达框、tesB(或yciA或cat1)表达框,基因组adhE位点和/或ldhA位点插入ter表达框。所述表达框所用启动子包括Pfnrs启动子。
本发明的第三方面,提供了一种质粒,所述的质粒包含插入基因,所述的插入基因包含丁酸合成相关基因。
优选的,所述的质粒还包含质粒骨架。
优选的,所述的质粒包含插入基因表达所需调控元件,例如启动子等等。
在本发明的一个具体实施方式中,所述的质粒骨架包括但不限于含有pBBR1复制子的质粒或pRE112质粒。
本发明的第四方面,提供了一种药物或功能性菌剂或药物组合物或药物佐剂或化妆品,所述的药物或功能性菌剂或药物组合物或药物佐剂或化妆品包括上述的益生菌。其中益生菌可以为一种或多种的组合。优选还包含药学上可接受的辅料。优选还可以包含除益生菌之外的其他活性成分。
本发明的第五方面,提供了一种药物或功能性菌剂或药物组合物或药物佐剂或化妆品的制备方法,所述的制备方法包括将上述益生菌在培养基中培养至对数期,然后用生理盐水清洗并重悬。
在本发明的一个具体实施方式中,所述的制备方法包括将上述益生菌在LB培养基中37℃培养至对数期,用生理盐水清洗并重悬至菌浓度达到2.5*1010CFU/mL。
本发明的第六方面,提供了一种饲料或饲料添加剂,所述的饲料或饲料添加剂包括上述的益生菌。其中益生菌可以为一种或多种的组合。优选还包含常规动物饲料所含成分。
当本发明所述的益生菌作为饲料添加剂时,其可以替代抗生素或者与抗生素并用,可以起到平衡动物生态系统,维持肠道稳态,例如在其体内形成了正常微生物菌群,为宿主合成主要的维生素,提供营养和阻止致病菌的入侵等等。
本发明的第七方面,提供了一种食品,所述的食品中包含上述的益生菌。其中,益生菌可以为一种或多种的组合。
优选的,所述的食品可以为酸奶、面包等等。
所述的食品可供人或非人动物食用。
本发明的第八方面,提供了一种上述的益生菌或药物或药物组合物或药物佐剂或功能性菌剂在化工、食品、医药、动物饲料或化妆品领域中的应用。
本发明的第九方面,提供了一种上述的益生菌或药物或药物组合物或药物佐剂或功能性菌剂在治疗或预防疾病中的应用,或者,在制备治疗或预防疾病的产品中的应用。
优选的,所述的疾病可以为炎症、免疫相关疾病、心理疾病、代谢性疾病等等。例如结直
肠炎、抑郁,改善肥胖或脂肪肝等。优选的,所述的产品可以为药物、或药物组合物或药物佐剂或功能性菌剂或食品或饲料或饲料添加剂或化妆品。
优选的,所述的疾病为结直肠炎,其中,改善结直肠炎症状包括但不限于降低粘膜损伤、缓解结肠长度变短或减少结肠中包括TNF-α、IL-1β、IL-6在内的促炎因子含量。
优选的,所述的疾病为抑郁,其中,改善抑郁症样行为包括但不限于如下方面:(1)减少放弃抵抗的行为,缓解抑郁情绪;(2)减少海马中包括炎症细胞因子IL-1β、细胞焦亡相关的膜穿孔蛋白消皮素D(gasdermin D,GSDMD)含量。
优选的,所述的疾病为肥胖或脂肪肝,其中,改善肥胖和脂肪肝症状包括但不限于(1)减轻体重;(2)减少脂肪量;(3)改善肥胖病理情况下的脂肪肝表型;(4)降低炎症水平。
本发明的第十方面,提供了一种上述的益生菌或药物或药物组合物或药物佐剂或功能性菌剂在改善结直肠炎症状中的应用,包括但不限于降低粘膜损伤、缓解结肠长度变短或减少结肠中包括TNF-α、IL-1β、IL-6在内的促炎因子含量。
本发明的第十一方面,提供了一种益生菌或药物或药物组合物或药物佐剂或功能性菌剂在改善抑郁症样行为中的应用,包括但不限于如下方面:(1)减少放弃抵抗的行为,缓解抑郁情绪;(2)减少海马中包括炎症细胞因子IL-1β、细胞焦亡相关的膜穿孔蛋白消皮素D(gasdermin D,GSDMD)含量。
本发明的第十二方面,提供了一种益生菌或药物或药物组合物或药物佐剂或功能性菌剂或化妆品在改善肥胖和脂肪肝症状表型中的应用,包括但不限于(1)减轻体重;(2)减少脂肪量;(3)改善肥胖病理情况下的脂肪肝表型;(4)降低炎症水平。
本发明的第十三方面,提供了一种治疗或预防疾病的方法,所述的方法包括向个体施加上述的益生菌或药物或药物组合物或药物佐剂或功能性菌剂。
优选的,所述的方法包括向个体施加治疗或预防有效量的上述的益生菌或药物或药物组合物或药物佐剂或功能性菌剂。
优选的,所述的疾病可以为炎症、免疫相关疾病、心理疾病、代谢性疾病等等。例如结直肠炎、抑郁,改善肥胖或脂肪肝等。
本申请的技术方案可以将原本不产生丁酸的益生菌稳定产生丁酸,对于原本可以产生丁酸的益生菌增加其产量,更重要的是,本申请获得的益生菌能够有效缓解溃疡性结直肠炎、改善抑郁症、肥胖和脂肪肝症状,可用于制备具有缓解溃疡性结直肠炎、改善抑郁症、肥胖和脂肪肝症状的食品、药物、饲料制品等,具有广泛的应用前景。
本发明所述的“插入基因”可以为外源基因或内源基因。其中,外源基因为改造前该生物体不含有的基因,即通过外源基因的插入使得生物体包含该基因;内源基因为改造前生物体已经包含的基因,即通过内源基因的插入使得生物体过表达或者含有超过该生物体原有拷贝数的该基因。当然,在本申请中插入基因为一个或多个,当插入基因为多个时,这些基因可以一部分外源一部分内源或者均为内源或均为外源。
本发明所述的“治疗”表示在疾病已开始发展后减缓、中断、阻止、控制、停止、减轻、或逆转一种体征、症状、失调、病症、或疾病的进展或严重性,但不一定涉及所有疾病相关体征、症状、病症、或失调的完全消除。
本发明所述的“预防”表示为了阻止或延迟疾病或病症或症状在机体内的发生而实施的方式。
本发明所述的“有效量”是指在以单个或多个剂量给予至个体或器官之后提供所希望的治疗或预防的本发明的产品(例如益生菌、药物、药物组合物、药物佐剂或功能性菌剂)的量或剂量。
本发明所述的“炎症”包括急性炎症,也包括慢性炎症。具体的,包括但不限于变质性炎症、渗出性炎症(浆液性炎、纤维素性炎、化脓性炎、出血性炎、坏死性炎、卡他性炎)、增生性炎症、特异性炎症(结核、梅毒、麻疯、淋巴肉芽肿等)。例如结直肠炎等。
本发明所述的“免疫相关疾病”包括但不限于GVHD(移植物抗宿主病)、银屑病、过敏、哮喘、心肌炎、肾炎、肝炎、系统性红斑狼疮、类风湿性关节炎、硬皮病、甲状腺功能亢进、原发性血小板减少性紫癜、自身免疫性溶血性贫血、溃疡性结肠炎、自身免疫性肝病、糖尿病、疼痛或神经障碍等。
本发明所述的“心理疾病”包括感觉障碍、知觉障碍、注意障碍、记忆障碍、思维障碍、情感障碍、意志障碍、行为障碍、意识障碍、智力障碍、人格障碍等。例如神经衰弱、焦虑症、疑病性神经症(疑病症)、癔病(癔症)、强迫症、恐怖症、抑郁等。
本发明所述的“代谢性疾病”包括代谢障碍和代谢旺盛引起的疾病,例如糖尿病、高尿酸血症、高脂血症、肥胖、脂肪肝、高血糖高渗综合征、低血糖症、痛风、蛋白质-能量营养不良症、维生素A缺乏病、坏血病、维生素D缺乏病或骨质疏松症等等。
本发明术语“包括”或“包含”是开放式的描述,含有所描述的指定成分或步骤,以及不会实质上影响的其他指定成分或步骤。
本发明所述的“个体”可以为人或动物(或非人动物),所述的动物(非人动物)可以为野生动物、动物园动物、经济动物、宠物、实验动物等等。优选的,所述的非人动物包括但不限于猪、牛、羊、马、驴、狐、貉、貂、骆驼、狗、猫、兔、鼠(例如大鼠、小鼠、豚鼠、仓鼠、沙鼠、龙猫、松鼠)、鱼或猴等等。
本发明所述的“和/或”包含该术语所连接的项目的所有组合,应视为各个组合已经单独地在本问列出。例如,“A和/或B”包含了“A”、“A和B”以及“B”。又例如,“A、B和/或C”包含了“A”、“B”、“C”、“A和B”、“A和C”、“B和C”以及“A和B和C”。
本发明所述的“药学上可接受的”是指既不显著刺激生物体也不抑制所施用的产品的活性物质的生物学活性及特性。
本发明所述的“药学上可接受的辅料”,包括但不限于载体、赋形剂、稀释剂、润湿剂、填充剂、粘合剂、润滑剂、崩解剂、抗氧化剂、缓冲剂、助悬剂、增溶剂、增稠剂、稳定剂、矫味剂和防腐剂等中的一种或多种,或者包括但不限于为益生菌的生长和繁殖提供环境的物质等。
本发明所述的药物可以采用任何合适的给药途径,例如胃肠道给药(例如口服)或非胃肠道给药(例如,静脉内、肌内、皮下、皮内、器官内、鼻内、眼内、滴注、脑内、鞘内、透皮、直肠内等)途径。
本发明所述的药物可以为任何合适的剂型,例如经胃肠道给药剂型或非经胃肠道给药剂型,优选包括但不限于片剂、丸剂、粉剂、颗粒剂、胶囊剂、锭剂、糖浆剂、液体、乳剂、微乳剂、
混悬剂、注射剂、喷雾剂、气雾剂、粉雾剂、洗剂、软膏剂、硬膏剂、糊剂、贴剂、滴眼剂、滴鼻剂、舌下片剂、栓剂、气雾剂、泡腾片、滴丸剂、凝胶剂等等。
本发明所述药物的各种剂型可以按照药学领域的常规生产方法制备。
本发明所述的药物可以含有重量比为0.01-100%(具体如,0.01%、0.1%、0.5%、1%、2%、3%、4%、5%、6%、7%、8%、9%、10%、20%、30%、40%、50%、60%、70%、80%、90%、95%、99%、100%)的所述益生菌。
以下,结合附图来详细说明本发明的实施例,其中:
图1:丁酸合成途径。
图2:改造后益生菌的丁酸产量。
图3:eEcN减轻小鼠的肠炎症状。A是eEcN对结直肠炎小鼠粘膜损伤的影响图;B是eEcN对结直肠炎小鼠结肠长度的影响图,左图为柱形图,右图为实际测量小鼠结肠长度图;C是eEcN对结直肠炎小鼠结肠中促炎因子含量的影响图;D是eEcN对结直肠炎小鼠结肠组织病理评分的影响图。
图4:eEcN缓解慢性不可预知温和应激(CUMS)诱导的小鼠抑郁行为。其中,con为对照组,eEcN为eEcN干预组,EcN为EcN对照组,Sal为模型组;A是强迫游泳测试时eEcN对抑郁小鼠的影响图;B是eEcN对eEcN对抑郁小鼠海马体中IL-1b的影响图;C是eEcN对抑郁小鼠海马体中消皮素D(GSDMD)的影响图。
图5:eEcN改善肥胖和脂肪肝症状。A是肝组织HE染色图;B是eEcN对肥胖小鼠脂肪量(左图)或瘦肉量(右图)的影响,C是eEcN对肥胖小鼠体重的影响图;D是eEcN对肥胖小鼠的血白细胞(WBC)或中性粒细胞(Gran)水平影响(涉及范围0.1-1.8)。
下面详细叙述本发明的实施方式,需要说明的是,本实施例是叙述性的,不是限定性的,不能以此限定本发明的保护范围。
本发明中所使用的原料,如无特殊说明,均为常规的市售产品;本发明中所使用的方法,如无特殊说明,均为本领域的常规方法。
实施例中利用自杀质粒同源重组构建大肠杆菌的方法如下:
以敲入、或敲除、或替换基因组位点上下游~1000bp为同源臂,在大肠杆菌S17-1中构建以pRE112为骨架,含有“目标插入位点上游同源臂-插入片段-目标插入位点下游同源臂”(敲入),或“目标敲除位点上游同源臂-目标敲除位点下游同源臂”(敲除),或“目标替换位点上游同源臂-替换片段-目标替换位点下游同源臂”(替换)片段的自杀质粒(suicide plasmid)。将含该自杀质粒的菌株接合转化至
Escherichia coli Nissle 1917(简称EcN)或缺失隐秘质粒pMUT1和/或pMUT2的EcN,其NCBI Taxonomy ID为316435,然后利用含有氯霉素的基本培养基平板进行第一轮单交换单克隆的筛选,PCR验证后得到第一轮交换阳性菌株。在含有10g/L蔗糖的LB培养基中过夜培养上述阳性菌株,促进第二轮双交换,再取菌液涂布含有10g/L蔗糖的LB平板得到单克隆,利用PCR验证和DNA测序得到最终基因组编辑成功菌株。
实施例中大肠杆菌的发酵培养条件:
挑取生长良好的单菌落接种于含LB液体培养基的摇瓶中,37℃,200r/min培养10h。再将种子液在装满培养基(M9基本培养基+15g/L葡萄糖+5g/L酵母粉)的14mL密封摇管中静置培养48h,检测培养基上清中丁酸含量。
实施例中HPLC测定丁酸产量的方法:
HPLC条件:Aminex HPX-87H(Bio-Rad,USA)色谱柱,5mmol/L稀硫酸流动相,紫外检测器,210nm检测波长,柱温50℃,流速0.6mL/min,20μL进样量。
实施例1:益生菌的制备
以缺失隐秘质粒pMUT1和pMUT2的EcN(参考文献:CRISPR-based curing and analysis of metabolic burden of cryptic plasmids in Escherichia coliNissle 1917,Eng Life Sci.2019Jun3;19(6):478-485.)为出发菌株。利用自杀质粒同源重组构建大肠杆菌,具体为:
首先敲除EcN菌株adhE和ldhA基因,并在基因组malEK(malE:糖ABC转运蛋白底物结合蛋白,malK:糖转运蛋白ATP结合蛋白,参见Development ofa synthetic live bacterial therapeutic for the human metabolic disease phenylketonuria,Nat Biotechnol.2018Oct;36(9):857-864)位点插入Pfnrs-phaA-hbd-Pfnrs-crt-ter-Pfnrs-tesB(见SEQ ID NO:1,其中,第93至1274位为phaA,第1301至2149位为hbd,第2177至2962位为crt,第2989至4182位为ter,第4280至5140位为tesB),测序正确后得到产丁酸益生菌M3。替换M3菌株malEK位点hbd-crt为phaB-phaJ基因,得到产丁酸益生菌M2。以M3为出发菌株,在adhE和ldhA两个位点分别插入Pfnrs-ter(见SEQ ID NO:2),得到含有三拷贝ter的产丁酸益生菌M3A8L8;替换M3A8L8菌株malEK位点phaA为thl基因,得到产丁酸益生菌M3A8L8T;替换M3A8L8菌株malEK位点phaA为atoB基因,得到产丁酸益生菌eEcN。替换eEcN菌株malEK位点tesB为yciA基因,得到产丁酸益生菌M3A8L8Y;替换eEcN菌株malEK位点tesB为cat1基因,得到产丁酸益生菌M3A8L8C;敲除EcN菌株adhE基因,malEK位点插入Pfnrs-atoB-hbd-Pfnrs-crt-ter-Pfnrs-tesB,adhE位点插入Pfnrs-ter,得到产丁酸益生菌M3A8;以eEcN为出发菌株,敲除frdA,得到产丁酸益生菌M3A9。表1汇总了实施例1构建菌株。
表1:本实施例构建的菌株
其中,atoB(见SEQ ID NO:4)、tesB和yciA(见SEQ ID NO:6)为EcN(GenBank:CP007799.1)来源序列,phaA(Uniprot Entry:P14611)为Cupriavidusnecator来源经大肠杆菌密码子优化后序列,thl(来源于Uniprot Entry:E3VJQ0,见SEQ ID NO:3)和cat1(来源于Uniprot Entry:W6N7A7,见SEQ ID NO:5)为Clostridium tyrobutyricum来源经大肠杆菌密码子优化后序列,hbd(Uniprot Entry:P52041)和crt(Uniprot Entry:P52046)为Clostridium acetobutylicum来源经大肠杆菌密码子优化后序列,phaB(来源于文献:Cloning and nucleotide sequences of genes relevant for biosynthesis of poly(3-hydroxybutyric acid)in Chromatium vinosum strain D,Eur J Biochem.1992Oct 1;209(1):135-50,见SEQIDNO:42)为Chromatium vinosum来源经大肠杆菌密码子优化后序列,phaJ(来源于Uniprot Entry:O32472,见SEQIDNO:43)为Aeromonas caviae来源经大肠杆菌密码子优化后序列,ter(Uniprot Entry:Q73Q47)为Treponema denticola来源经大肠杆菌密码子优化后序列。表2引物用于构建包含目的基因的自杀质粒。
如图2所示,野生型EcN不生产丁酸,改造后的益生菌发酵48h丁酸产量0.3~1.6g/L,选取中间产量菌株eEcN(1.4g/L)应用于后续研究。
表2:实施例1中应用的引物
实施例2:eEcN在缓解葡聚糖硫酸钠(DSS)诱导的结直肠炎小鼠疾病症状中的应用
取体重18-22g的健康雄性C57BL/6J小鼠24只,每组6只小鼠随机分为4组:空白组(常规饮水+灌胃生理盐水)、模型组(2%DSS饮水+灌胃生理盐水)、eEcN干预组(2%DSS饮水+灌胃eEcN)、EcN对照组(2%DSS饮水+灌胃EcN)。以2%DSS饮水5天+常规饮水7天为一个循环,共循环三次,模型组、eEcN干预组和EcN对照组小鼠产生慢性肠炎症状。每两天灌胃一次,eEcN和EcN灌胃剂量为5×109CFU/只,其它组灌胃等体积生理盐水。
造模期间(即用DSS处理期间),每两天根据小鼠体重、粪便性状和便血情况,计算得出小鼠的疾病活动指数(Disease activity index,DAI)。具体为:疾病活动指数结合动物的体重下降百分率(体重不变为0,1-5为1分,5-10为2分,10-15为3分,大于15为4分)、大便黏稠度(正常为0,松散的大便为2分,腹泻为4分)和大便出血(正常0分,隐血阳性为2分,显性出血为4分)三种情况进行综合评分,将3项结果的总分除以3即得到DAI值。即DAI=(体重指数+大便形状+出血情况)/3。
在第36天处死小鼠后,测量小鼠结肠长度并记录。取结直肠组织,利用RT-PCR检测促炎因子含量,制作结肠石蜡切片并进行HE染色。
实验结果如图3所示,eEcN可以减轻小鼠的肠炎症状,包括降低粘膜损伤(图3A),减轻结肠缩短(图3B),减少促炎细胞因子(图3C)以及减少DAI疾病评分(图3D)。
实施例3:eEcN在缓解慢性不可预知温和应激(CUMS)诱导的抑郁样行为小鼠中的应用
取八周龄的健康雄性C57BL/6J小鼠60只,随机分配10只作为对照组,剩余50只进行为期4周的CUMS造模。造模4周后进行行为学测试,将造模成功的小鼠随机平均分配成3组。进而,目前小鼠被分为4组:对照组(正常饲养8周);模型组(CUMS造模8周,第5周开始灌胃生理盐水)、eEcN干预组(CUMS造模8周,第5周开始灌胃eEcN)、EcN对照组(CUMS造模8周,第5周开始灌胃
EcN)。每天灌胃一次,eEcN和EcN灌胃剂量为1×109CFU/只,对照组和模型组灌胃等体积生理盐水。
在第8周灌胃结束的第二天进行行为学测试,测试的同时仍灌胃。当行为学测试结束后,处死小鼠,心脏灌流4%多聚甲醛后取小鼠全脑,剥离海马,利用RT-PCR检测促炎因子含量。
实验结果如图4所示,eEcN可以增加强迫游泳(图A)的抑郁小鼠挣扎时长,缓解其抑郁表型,并减少抑郁小鼠海马中IL-1β(图B)和消皮素D(GSDMD,图C)含量。
实施例4:eEcN在改善小鼠肥胖和脂肪肝表型的应用
取4-5周龄的健康雄性C57BL/6J小鼠(体重18-22g)22只,随机分配6只作为对照组,剩余16只用60%(kcal)高脂纯化饲料(HFD)进行肥胖造模。持续8-12周直至小鼠肥胖模型诱导成功,将造模成功的小鼠随机平均分配成3组。至此,小鼠被分为4组:对照组(正常饮食组,和模型组同步灌胃生理盐水,简称ND);模型组(HFD造模,造模成功后灌胃生理盐水,简称HFD)、eEcN干预组(HFD造模,造模成功后灌胃eEcN,简称HFD+eEcN)、EcN对照组(HFD造模,造模成功后灌胃EcN,简称HFD+EcN。每四天灌胃一次,eEcN和EcN灌胃剂量为1×109CFU/只,对照组和模型组灌胃等体积生理盐水。
灌胃期间每四天定时称体重并记录体重数据,灌胃32天后,将全部小鼠置于EchoMRI小动物体成分分析仪中进行体脂成分检测,记录小鼠瘦肉量(Lean mass)和脂肪量(Fat mass)。接着对小鼠进行安乐死和采血,全血样本检测白细胞和中性粒细胞水平,取肝脏组织进行HE染色,以观察脂肪肝表型。
实验结果如图5所示,eEcN可以减轻肥胖小鼠体重及其脂肪量,同时改善小鼠肥胖病理情况下的脂肪肝表型,降低肥胖小鼠全身炎症水平。
虽然本发明已以较佳实施例公开如上,但其并非用以限定本发明,任何熟悉此技术的人,在不脱离本发明的精神和范围内,都可做各种的改动与修饰,因此本发明的保护范围应该以权利要求书所界定的为准。
Claims (20)
- 一种产丁酸的益生菌,其特征在于,所述益生菌的基因组中包含插入基因,所述的插入基因包含丁酸合成相关基因,所述的丁酸合成相关基因包括3-羟基丁酰辅酶A脱氢酶基因、3-羟基丁酰辅酶A脱水酶基因和/或烯酰辅酶A还原酶基因。
- 根据权利要求1所述的益生菌,其特征在于,所述的丁酸合成相关基因还包括乙酰乙酰辅酶A硫解酶基因和/或乙酰辅酶A乙酰基转移酶基因。
- 根据权利要求1或2所述的益生菌,其特征在于,所述的丁酸合成相关基因还包含酰基辅酶A硫酯酶基因和/或辅酶A转移酶基因。
- 根据权利要求1-3任一所述的益生菌,其特征在于,所述的插入基因中各基因为单拷贝或多拷贝。
- 根据权利要求1-4任一所述的益生菌,其特征在于,所述的插入基因在质粒中表达或在染色体上表达。
- 根据权利要求1-5任一所述的益生菌,其特征在于,所述的益生菌不表达或降低表达丁酸合成竞争途径相关基因;优选的,所述的丁酸合成竞争途径相关基因包括乳酸脱氢酶A基因、乙醛乙醇脱氢酶基因和/或富马酸还原酶基因中的一种或两种以上的组合。
- 根据权利要求1-6任一所述的益生菌,其特征在于,所述的益生菌选自酵母菌、益生芽孢菌、丁酸梭菌、乳杆菌、双歧杆菌、肠球菌、链球菌、放线菌或大肠杆菌。
- 一种权利要求1-7任一所述的益生菌的构建方法,其特征在于,所述的构建方法包括将插入基因导入益生菌中;优选的,所述的构建方法还包括敲低或敲除丁酸合成竞争途径相关基因。
- 根据权利要求8所述的构建方法,其特征在于,所述的插入基因包含丁酸合成相关基因,所述的丁酸合成相关基因包括3-羟基丁酰辅酶A脱氢酶基因、3-羟基丁酰辅酶A脱水酶基因和/或烯酰辅酶A还原酶基因。
- 根据权利要求8或9所述的构建方法,其特征在于,所述的丁酸合成相关基因还包括乙酰乙酰辅酶A硫解酶基因和/或乙酰辅酶A乙酰基转移酶基因。
- 根据权利要求8-10任一所述的构建方法,其特征在于,所述的丁酸合成相关基因还包含酰基辅酶A硫酯酶基因和/或辅酶A转移酶基因。
- 根据权利要求8-11任一所述的构建方法,其特征在于,所述的插入基因插入益生菌染色体基因组的malEK、adhE或ldhA位点。
- 根据权利要求8所述的构建方法,其特征在于,所述的丁酸合成竞争途径相关基因包括乳酸脱氢酶A基因、乙醛乙醇脱氢酶基因和/或富马酸还原酶基因中的一种或两种以上的组合。
- 根据权利要求8-13任一所述的构建方法,其特征在于,所述的益生菌选自酵母菌、益生芽孢菌、丁酸梭菌、乳杆菌、双歧杆菌、肠球菌、链球菌、放线菌或大肠杆菌。
- 一种药物或饲料添加剂或食品或化妆品,其特征在于,所述的药物或饲料添加剂或食品或化妆品包括权利要求1-7任一所述的益生菌。
- 一种权利要求1-7任一所述的益生菌或权利要求15所述的药物或饲料添加剂或食品或化妆品在化工、食品、医药、动物饲料或化妆品领域中的应用。
- 一种权利要求1-7任一所述的益生菌在制备治疗或预防疾病的产品中的应用;优选的,所述的疾病可以为炎症、免疫相关疾病、心理疾病或代谢性疾病。
- 根据权利要求17所述的应用,其特征在于,所述的疾病为结直肠炎,其中,改善结直肠 炎症状包括但不限于降低粘膜损伤、缓解结肠长度变短或减少结肠中包括TNF-α、IL-1β、IL-6在内的促炎因子含量;或者,所述的疾病为抑郁,其中,改善抑郁症样行为包括但不限于如下方面:(1)减少放弃抵抗的行为,缓解抑郁情绪;(2)减少海马中包括炎症细胞因子IL-1β、细胞焦亡相关的膜穿孔蛋白消皮素D(gasdermin D,GSDMD)含量;或者,所述的疾病为肥胖或脂肪肝,其中,改善肥胖和脂肪肝症状包括但不限于(1)减轻体重;(2)减少脂肪量;(3)改善肥胖病理情况下的脂肪肝表型;(4)降低炎症水平。
- 一种治疗或预防疾病的方法,其特征在于,所述的方法包括向个体施加权利要求1-7任一所述的益生菌或权利要求15所述的药物。
- 根据权利要求19所述的方法,其特征在于,所述的疾病可以为炎症、免疫相关疾病、心理疾病或代谢性疾病;优选的,所述的疾病为结直肠炎、抑郁,改善肥胖或脂肪肝等。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210323936.2A CN114774338B (zh) | 2022-03-29 | 2022-03-29 | 一种产丁酸的益生菌及其构建方法和应用 |
CN202210323936.2 | 2022-03-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023185760A1 true WO2023185760A1 (zh) | 2023-10-05 |
Family
ID=82427771
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2023/084163 WO2023185760A1 (zh) | 2022-03-29 | 2023-03-27 | 一种产丁酸的益生菌及其构建方法和应用 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN114774338B (zh) |
WO (1) | WO2023185760A1 (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114774338B (zh) * | 2022-03-29 | 2023-08-08 | 北京航空航天大学 | 一种产丁酸的益生菌及其构建方法和应用 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140186902A1 (en) * | 2011-12-16 | 2014-07-03 | Invista North America S. A R.L. | METHODS OF PRODUCING 6-CARBON CHEMICALS VIA CoA-DEPENDENT CARBON CHAIN ELONGATION ASSOCIATED WITH CARBON STORAGE |
CN104789487A (zh) * | 2014-01-17 | 2015-07-22 | 逢甲大学 | 分别可生产丁酸和正丁醇的菌株、及生成正丁醇的方法 |
US20180135059A1 (en) * | 2015-04-16 | 2018-05-17 | William Marsh Rice University | Synthesis of omega functionalized products |
CN110438056A (zh) * | 2019-08-12 | 2019-11-12 | 江南大学 | 一株产正丁酸的大肠杆菌工程菌的构建及应用 |
CN111304140A (zh) * | 2020-03-05 | 2020-06-19 | 清华大学 | 产(r)-3-羟基丁酸的重组肠道菌及其构建方法 |
CN114774338A (zh) * | 2022-03-29 | 2022-07-22 | 北京航空航天大学 | 一种产丁酸的益生菌及其构建方法和应用 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2868113A1 (en) * | 2011-03-22 | 2012-09-27 | Opx Biotechnologies, Inc. | Microbial production of chemical products and related compositions, methods and systems |
WO2012135731A2 (en) * | 2011-04-01 | 2012-10-04 | The Regents Of The University Of California | Alcohol production from recombinant microorganisms |
CN104220601A (zh) * | 2011-12-16 | 2014-12-17 | 英威达技术有限责任公司 | 经与碳储存相关的CoA 依赖性碳链延长制备6 碳化学品的方法 |
US20140371417A1 (en) * | 2013-04-26 | 2014-12-18 | Genomatica, Inc. | Microorganisms and methods for production of 4-hydroxybutyrate, 1,4-butanediol and related compounds |
JP6868562B2 (ja) * | 2014-10-31 | 2021-05-19 | ペンデュラム セラピューティクス, インコーポレイテッド | 障害の微生物的処置および診断に関する方法および組成物 |
WO2017223025A1 (en) * | 2016-06-21 | 2017-12-28 | University Of Florida Research Foundation, Incorporated | Engineering escherichia coli for production of butyric acid |
WO2021062048A2 (en) * | 2019-09-24 | 2021-04-01 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Methods and systems for modulating hepatic gaba production or release to alter food intake in monogastric species |
CN111073823B (zh) * | 2019-12-27 | 2021-08-03 | 天津科技大学 | 一种高产丁酸乙酯酿酒酵母菌株及其构建方法与用途 |
WO2021195577A2 (en) * | 2020-03-26 | 2021-09-30 | Persephone Biosciences, Inc. | Compositions for modulating gut microflora populations, enhancing drug potency and treating viral infections, and methods for making and using same |
-
2022
- 2022-03-29 CN CN202210323936.2A patent/CN114774338B/zh active Active
-
2023
- 2023-03-27 WO PCT/CN2023/084163 patent/WO2023185760A1/zh unknown
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140186902A1 (en) * | 2011-12-16 | 2014-07-03 | Invista North America S. A R.L. | METHODS OF PRODUCING 6-CARBON CHEMICALS VIA CoA-DEPENDENT CARBON CHAIN ELONGATION ASSOCIATED WITH CARBON STORAGE |
CN104789487A (zh) * | 2014-01-17 | 2015-07-22 | 逢甲大学 | 分别可生产丁酸和正丁醇的菌株、及生成正丁醇的方法 |
US20180135059A1 (en) * | 2015-04-16 | 2018-05-17 | William Marsh Rice University | Synthesis of omega functionalized products |
CN110438056A (zh) * | 2019-08-12 | 2019-11-12 | 江南大学 | 一株产正丁酸的大肠杆菌工程菌的构建及应用 |
CN111304140A (zh) * | 2020-03-05 | 2020-06-19 | 清华大学 | 产(r)-3-羟基丁酸的重组肠道菌及其构建方法 |
CN114774338A (zh) * | 2022-03-29 | 2022-07-22 | 北京航空航天大学 | 一种产丁酸的益生菌及其构建方法和应用 |
Non-Patent Citations (3)
Title |
---|
BAI YANFEN, MANSELL THOMAS J.: "Production and Sensing of Butyrate in a Probiotic E. coli Strain", INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, vol. 21, no. 10, pages 3615, XP093094689, DOI: 10.3390/ijms21103615 * |
HE FEIFEI; QIN SHIWEN; YANG ZHI; BAI XUEHUI; SUO YUKAI; WANG JUFANG: "Butyric acid production from spent coffee grounds by engineered Clostridium tyrobutyricum overexpressing galactose catabolism genes", BIORESOURCE TECHNOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 304, 7 February 2020 (2020-02-07), AMSTERDAM, NL , XP086081350, ISSN: 0960-8524, DOI: 10.1016/j.biortech.2020.122977 * |
LIM JAE HYUNG; SEO SANG WOO; KIM SE YEON; JUNG GYOO YEOL: "Refactoring redox cofactor regeneration for high-yield biocatalysis of glucose to butyric acid inEscherichia coli", BIORESOURCE TECHNOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 135, 2 October 2012 (2012-10-02), AMSTERDAM, NL , pages 568 - 573, XP028579606, ISSN: 0960-8524, DOI: 10.1016/j.biortech.2012.09.091 * |
Also Published As
Publication number | Publication date |
---|---|
CN114774338B (zh) | 2023-08-08 |
CN114774338A (zh) | 2022-07-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3065748B1 (en) | A bacteroides thetaiotaomicron strain and its use in reducing inflammation | |
TWI746486B (zh) | 包含細菌菌株之組合物 | |
US9937211B2 (en) | Composition of Roseburia hominis | |
JP6894382B2 (ja) | 免疫シグナル伝達をもたらし、かつ/または腸管バリア機能に影響を与え、かつ/または代謝状態を調節するためのポリペプチドの使用 | |
JP7178333B2 (ja) | ラクトバチルス・パラカゼイを含む老化遅延組成物、老化遅延組成物の製造方法、および老化遅延組成物の製造におけるラクトバチルス・パラカゼイの使用 | |
CA2964480A1 (en) | Methods and compositions relating to microbial treatment and diagnosis of disorders | |
CN114984057A (zh) | 包含细菌菌株的组合物 | |
JP6669703B2 (ja) | 改変されたグラム陽性菌及びその使用 | |
JP2009269906A (ja) | 抗炎症活性を有するラクトバチルス分離株及びそれらの利用 | |
JP7055520B2 (ja) | アッカーマンシア・ムシニフィラeb-amdk27菌株およびその使用 | |
WO2023185760A1 (zh) | 一种产丁酸的益生菌及其构建方法和应用 | |
JP6629955B2 (ja) | 減量脂質低下のための形質転換体およびその構築方法、並びにその応用 | |
JP7262127B2 (ja) | 新規乳酸菌およびそれを含有する組成物 | |
TWI621708B (zh) | 免疫調節 | |
Zhao et al. | Research progress of naturally fermented yogurt with lactic acid bacteria in Xinjiang: a review of anti-constipation probiotics | |
Khudojberdievich | The role of the gut microbiota in nutrition and health | |
AU2018205072B2 (en) | Immune modulation | |
CN115590844B (zh) | 中康酸在制备用于预防或治疗代谢综合征的药物中的应用 | |
CN115590865B (zh) | 褐藻寡糖在制备改善肠道菌群紊乱制品中的应用 | |
TWI750342B (zh) | 包含菌株之組合物及其用途、製法及產品 | |
Xu et al. | Microencapsulated essential oils alleviate diarrhea in weaned piglets by modulating the intestinal microbial barrier as well as not inducing antibiotic resistance: a field research | |
WO2022261393A1 (en) | Surface layer protein a (slpa) as a therapeutic agent for the treatment of inflammatory diseases | |
EP4179087A1 (en) | Nutritional composition comprising mir-3184 | |
CN106978431A (zh) | 一种乳酸乳球菌MG1363介导的pBpp重组蛋白表达菌株及其功能验证方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23778125 Country of ref document: EP Kind code of ref document: A1 |